We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Fujifilm Begins US Phase II Clinical Trial of Avigan for COVID-19 Patients and Increases Production

By HospiMedica International staff writers
Posted on 17 Apr 2020
Print article
Image: Avigan: Mechanism of action (Photo courtesy of FUJIFILM Corporation)
Image: Avigan: Mechanism of action (Photo courtesy of FUJIFILM Corporation)
FUJIFILM Corporation (Tokyo, Japan) has initiated a US phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug Avigan® Tablet (generic name favipiravir) for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus. Avigan was the first-ever antiviral medicine to be approved for use as a treatment for COVID-19 in China.

Avigan Tablet was approved for manufacture and sale in Japan in 2014 as an influenza antiviral drug. The drug is to be considered for use only when there is an outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are either not effective or insufficiently effective, and the Japanese government decides to use the drug as a countermeasure against such influenza viruses. Avigan is not approved for distribution in the US or any overseas countries.

Avigan selectively inhibits RNA polymerase necessary for influenza virus replication. Due to its action mechanism, Avigan is expected to potentially have an antiviral effect on the new coronavirus, because similar to influenza viruses, coronaviruses are single-stranded RNA viruses that also depend on viral RNA polymerase. In March, Fujifilm commenced a phase III clinical trial of Avigan for COVID-19 patients in Japan.

The clinical trial of Avigan Tablet in the US will enroll approximately 50 patients with COVID-19, in collaboration with Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School. FUJIFILM has reaffirmed that it will continue to work to establish a treatment method for COVID-19 patients by conducting clinical trials, and to contribute towards ending the spread of the global pandemic by increasing the production of Avigan in collaboration with its strategic partners. In early March, FUJIFILM had already began increasing its production of Avigan and now plan to accelerate the production of its influenza antiviral drug through cooperation with domestic and overseas partners for responding to the needs of the Japanese government and other countries.


Gold Member
12-Channel ECG
CM1200B
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Wireless Handheld Ultrasound System
TE Air

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.